Hydroxyzine
| Evidence Level: L3 | Predicted Indications: 5 |
Table of Contents
Hydroxyzine: From Historical Use (Not Documented) to Allergic Urticaria
One-Sentence Summary
Hydroxyzine is a first-generation H1-antihistamine; the original UK-licensed indication is not documented in this evidence pack. The TxGNN model predicts it may be effective for Allergic Urticaria, with 0 clinical trials and 20 publications currently supporting this direction, most of which describe the antihistamine drug class rather than hydroxyzine specifically.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no marketing authorisation record available) |
| Predicted New Indication | Allergic urticaria |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L3 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data for hydroxyzine is not available in this evidence pack. Based on the pharmacological class it belongs to, hydroxyzine is a first-generation H1 histamine receptor antagonist. It directly blocks the vasodilation and pruritus caused by histamine release from mast cells — the core pathophysiological mechanism underlying urticaria.
The literature supporting this prediction largely concerns second-generation antihistamines (cetirizine, levocetirizine, bilastine) rather than hydroxyzine itself. Notably, cetirizine is a carboxylated metabolite of hydroxyzine, so this evidence represents an indirect, class-effect relationship rather than drug-specific data. One position statement (PMID 31582993) explicitly names hydroxyzine among first-generation agents used historically for urticaria, but also flags tolerability concerns relative to newer agents.
Because urticaria is fundamentally a histamine-driven condition and hydroxyzine’s H1-antagonism is well established pharmacologically, the mechanistic rationale is sound. However, the absence of hydroxyzine-specific randomised trials for allergic urticaria means the evidence base rests on class-level reasoning rather than direct proof.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31582993 | 2019 | Review/Position Statement | Allergy Asthma Clin Immunol | Names hydroxyzine among first-generation antihistamines used for urticaria, but recommends newer agents as first-line due to sedation/cognitive risk |
| 39532327 | 2024 | Case Report | BMJ Case Reports | Describes aquagenic urticaria management, illustrating continued clinical role of antihistamines in physical urticarias |
| 28913986 | 2017 | Review | Allergy Asthma Immunol Res | Reviews chronic spontaneous urticaria treatment ladder; notes hydroxyzine historically used at high doses when second-generation agents insufficient |
| 21793329 | 2010 | Open-label Multicentre Study | Chin J Physiol | Levocetirizine effective for allergic rhinitis and urticaria in Taiwanese patients (class-effect evidence) |
| 22686617 | 2012 | Review | Drugs | Phase III evidence for bilastine in allergic rhinoconjunctivitis and urticaria |
| 18336052 | 2008 | PK/PD Review | Clin Pharmacokinet | Comparative pharmacokinetics/pharmacodynamics of desloratadine, fexofenadine and levocetirizine |
| 16278258 | 2005 | Review | Ann Pharmacother | Efficacy and safety review of oral antihistamines for allergic rhinitis and chronic idiopathic urticaria |
| 18201439 | 2007 | Review | Allergy Asthma Proc | Levocetirizine reviewed for allergic rhinitis and chronic idiopathic urticaria |
| 19808127 | 2009 | Review | Clin Ther | Levocetirizine efficacy in seasonal/perennial allergic rhinitis and chronic idiopathic urticaria, adults and children |
| 1981354 | 1990 | Review | Drugs | Cetirizine (hydroxyzine’s carboxylated metabolite) reviewed for chronic urticaria, without CNS depressant effects of hydroxyzine |
UK Market Information
No UK marketing authorisation is currently held for hydroxyzine under this evidence pack (market status: Not marketed, 0 authorisations recorded). Should hydroxyzine’s UK licence status change, this section should be updated with MHRA product licence numbers, formulations and BNF classification.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic link (H1-receptor antagonism blocking histamine-mediated wheal/flare) is biologically sound and supported by class-effect literature (L3), but no clinical trials or hydroxyzine-specific RCTs for allergic urticaria exist in this evidence pack, and key drug-level safety data (warnings, contraindications, MOA) are currently missing.
To proceed, the following is needed:
- SmPC warnings and contraindications (currently a blocking data gap)
- Confirmed mechanism of action documentation from DrugBank or equivalent source
- Hydroxyzine-specific clinical evidence for allergic urticaria (current literature largely addresses related second-generation antihistamines)
- Confirmation of UK marketing/licensing status before any prescribing recommendation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.